LumiSTAR Biotechnology

@lumistarbiotech.com

LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, kidney failure and cancer. Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates.

lumistarbiotech.com

LumiSTAR Biotechnology's Company Logos

LumiSTAR Biotechnology's Brand Colors

Hex Code

Color name

RGB

HSL

CMYK

#1CBBB4

Java

28, 187, 180

177, 74, 42

85, 0, 4, 27

#F6F9F9

Porcelain

246, 249, 249

180, 20, 97

1, 0, 0, 2

#01578C

Orient

1, 87, 140

203, 99, 28

99, 38, 0, 45

About LumiSTAR Biotechnology

LumiSTAR Biotechnology is at the forefront of innovation in cell therapy and drug discovery, utilizing induced pluripotent stem cell (iPSC) technology. Their pioneering pipeline of cell therapies aims to revolutionize the treatment of various diseases, from neurodegenerative conditions like Parkinson’s and Alzheimer’s to CKD and cancer. In addition to cell therapy, LumiSTAR boasts a cutting-edge high-throughput drug screening platform, leveraging iPSC and bioimaging technologies to develop novel drugs effectively.

Their unique triple core technology platform integrates iPSCs, viral vectors, and genetically encoded tools to provide advanced solutions for drug discovery and cell therapy. With a seasoned management team led by CEO Yu-Fen Chang and COO Min-Wen Chung, LumiSTAR is committed to pushing the boundaries of regenerative medicine and bioimaging. For inquiries or collaborations, visit their office in Taipei City or reach out via phone or email to unlock new possibilities in healthcare and research.